Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

Autor: Sehn, Laurie H, Chua, Neil, Mayer, Jiri, Dueck, Gregg, Trněný, Marek, Bouabdallah, Kamal, Fowler, Nathan, Delwail, Vincent, Press, Oliver, Salles, Gilles, Gribben, John, Lennard, Anne, Lugtenburg, Pieternella J, Dimier, Natalie, Wassner-Fritsch, Elisabeth, Fingerle-Rowson, Günter, Cheson, Bruce D

Publikováno v: In The Lancet Oncology August 2016 17(8):1081-1093

Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis

Autor: Hasan, Syed Khizer ^*, Mays, Ashley N. ^*, Ottone, Tiziana, Ledda, Antonio, La Nasa, Giorgio, Cattaneo, Chiara, Borlenghi, Erika, Melillo, Lorella, Montefusco, Enrico, Cervera, José, Stephen, Christopher, Satchi, Gnanam, Lennard, Anne, Libura, Marta, Byl, Jo Ann W., Osheroff, Neil, Amadori, Sergio, Felix, Carolyn A., Voso, Maria Teresa, Sperr, Wolfgang R., Esteve, Jordi, Sanz, Miguel A., Grimwade, David, Lo-Coco, Francesco

Publikováno v: In Blood 15 October 2008 112(8):3383-3390

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas

Autor: Illidge, Tim, Pro, Barbara, Trumper, Lorenz, O'Connor, Owen A, Advani, Ranjana, Iyer, Swaminathan, Bartlett, Nancy L, Christensen, Jacob Haaber, Morschhauser, Frank, Domingo-Domenech, Eva, Rossi, Giuseppe, Kim, Won Seog, Feldman, Tatyana, Lennard, Anne, Belada, David, Illés, Árpád, Tobinai, Kensei, Tsukasaki, Kunihiro, Yeh, Su-Peng, Zinzani, Pier-Luigi, Little, Meredith, Manley, Thomas, Rao, Shangbang, Fanale, Michelle, Horwitz, Steven

Publikováno v: Illidge, T, Pro, B, Trumper, L, O'Connor, O A, Advani, R, Iyer, S, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Lennard, A, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Zinzani, P-L, Little, M, Manley, T, Rao, S, Fanale, M & Horwitz, S 2019, ' The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas ', 24th European Hematology Association Congress (EHA), Amsterdam, Netherlands, 13/06/2019-16/06/2019 . < https://library.ehaweb.org/eha/2019/24th/266687/tim.illidge.the.echelon-2.trial.results.of.a.randomized.double-blind.phase.3.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dps1070 >

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::a0ff05c9eaed028028506508b6b53207
https://portal.findresearcher.sdu.dk/da/publications/5dee6ce1-fe62-4c0f-8bf6-f8ec6066dc1f

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.